Validation of the GenesWell BCT Score in Young Asian Women With HR+/HER2− Early Breast Cancer

Validation of the GenesWell BCT Score in Young Asian Women With HR+/HER2− Early Breast Cancer

BackgroundThe prognostic or predictive value of commonly used multigene assays in young patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) early breast cancer is unclear. In this study, we assessed the prognostic value of the GenesWell BCT assay...

Full description

Bibliographic Details
Main Authors: Mi Jeong Kwon, Jai Min Ryu, Soo Youn Cho, Seok Jin Nam, Seok Won Kim, Jeeyeon Lee, Soo Jung Lee, Ji-Young Park, Ho Yong Park, Sungjun Hong, Kyunga Kim, Jinil Han, Youngho Moon, Young Kee Shin, Jeong Eon Lee
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Oncology
Subjects:
GenesWell BCT assay
BCT score
prognostic value
predictive value
young breast cancer patients
HR+/HER2− early breast cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.588728/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.588728/full

Similar Items